ID29021A - Komposisi galantamina pelepasan terkontrol - Google Patents

Komposisi galantamina pelepasan terkontrol

Info

Publication number: ID29021A
Authority: ID; Indonesia
Prior art keywords: galantamina; composition; controlled; controlled galantamina
Prior art date: 1998-12-24

Application number

IDW00200101372A

Other languages

English (en)

Inventor

John Paul Mcgee

Paul Marie Victor Gilis

Marc Maurice Germain De Weer

Valentin Florent Victor Conde

Herman Johannes Catheri Bruijn

Frederic Anne Rodolf Van Dycke

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-24

Filing date

1999-12-20

Publication date

2001-07-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-12-20 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2001-07-26 Publication of ID29021A publication Critical patent/ID29021A/id

Links

229960003980 galantamine Drugs 0.000 title 1
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

IDW00200101372A 1998-12-24 1999-12-20 Komposisi galantamina pelepasan terkontrol ID29021A (id)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98204447		1998-12-24

Publications (1)

Publication Number	Publication Date
ID29021A true ID29021A (id)	2001-07-26

Family

ID=8234559

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IDW00200101372A ID29021A (id)	1998-12-24	1999-12-20	Komposisi galantamina pelepasan terkontrol

Country Status (35)

Country	Link
US (3)	US7160559B1 (id)
EP (1)	EP1140105B1 (id)
JP (1)	JP2002533396A (id)
KR (1)	KR100437105B1 (id)
CN (1)	CN100370990C (id)
AP (1)	AP1414A (id)
AR (2)	AR022008A1 (id)
AT (1)	ATE252386T1 (id)
AU (1)	AU775914B2 (id)
BG (1)	BG65306B1 (id)
BR (1)	BR9916835A (id)
CA (1)	CA2358062C (id)
CZ (1)	CZ301658B6 (id)
DE (1)	DE69912311T2 (id)
DK (1)	DK1140105T3 (id)
EA (1)	EA004936B1 (id)
EE (1)	EE04996B1 (id)
ES (1)	ES2211215T3 (id)
HR (1)	HRP20010463B1 (id)
HU (1)	HUP0104778A3 (id)
ID (1)	ID29021A (id)
IL (2)	IL143899A0 (id)
MY (1)	MY122411A (id)
NO (1)	NO327988B1 (id)
NZ (1)	NZ511643A (id)
OA (1)	OA11740A (id)
PL (1)	PL349501A1 (id)
PT (1)	PT1140105E (id)
SI (1)	SI1140105T1 (id)
SK (1)	SK287676B6 (id)
TR (1)	TR200101822T2 (id)
TW (1)	TWI262079B (id)
UA (1)	UA79578C2 (id)
WO (1)	WO2000038686A1 (id)
ZA (1)	ZA200105132B (id)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5558648B2 (ja)	1998-11-23	2014-07-23	デイビス、ボニー	アセチルコリンエステラーゼ阻害剤のための投与製剤
OA11740A (en)	1998-12-24	2005-05-13	Janssen Pharmaceutica Nv	Controlled release galantamine composition.
CA2310950C (en) *	2000-04-03	2005-11-08	Janssen Pharmaceutica N.V.	An efficacious dosage regiment of galantamine that reduces side effects
CA2310926C (en) *	2000-04-03	2002-10-15	Janssen Pharmaceutica N.V.	A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10134038A1 (de) *	2001-07-12	2003-02-06	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
WO2003032914A2 (en) *	2001-10-17	2003-04-24	Eisai Co., Ltd.	Methods for treating substance abuse with cholinesterase inhibitors
FR2842735B1 (fr)	2002-07-26	2006-01-06	Flamel Tech Sa	Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) *	2002-08-03	2004-02-19	Hf Arzneimittelforschung Gmbh	Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
ATE359075T1 (de)	2002-12-20	2007-05-15	Niconovum Ab	Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
ITMI20030827A1 (it) *	2003-04-18	2004-10-19	Unihart Corp	Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en)	2003-12-15	2007-07-31	Pgxhealth Llc	CDK5 genetic markers associated with galantamine response
US20050142193A1 (en) *	2003-12-31	2005-06-30	Lijuan Tang	Galantamine formulations
EP2340813A1 (en) *	2003-12-31	2011-07-06	Actavis Group PTC ehf.	Solid dosage formulations of galantamine
CA2551946A1 (en) *	2003-12-31	2005-07-21	Actavis Group Hf	Immediate, controlled and sustained release formulations of galantamine
GB0408308D0 (en) *	2004-04-14	2004-05-19	Vectura Ltd	Pharmaceutical compositions
US20090208579A1 (en) *	2004-12-27	2009-08-20	Eisai R & D Management Co., Ltd.	Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
AU2005320547B2 (en) *	2004-12-27	2009-02-05	Eisai R & D Management Co., Ltd.	Method for stabilizing anti-dementia drug
JP5597343B2 (ja) *	2005-04-28	2014-10-01	エーザイ・アール・アンド・ディー・マネジメント株式会社	抗痴呆薬を含有する組成物
EP1933816A1 (en) *	2005-09-05	2008-06-25	Ranbaxy Laboratories, Ltd.	Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) *	2005-10-10	2007-04-26	Gore Subhash P	Galantamine compositions
JP5694645B2 (ja)	2006-03-16	2015-04-01	ニコノヴァムエービーＮｉｃｏｎｏｖｕｍＡｂ	改善された嗅ぎたばこ組成物
JP5826456B2 (ja) *	2006-04-26	2015-12-02	アルファファームピーティーワイリミテッド	コーティングされていない分離したユニットおよび延長放出マトリクスを含む制御放出配合物
WO2008062426A2 (en) *	2006-08-02	2008-05-29	Emcure Pharmaceuticals Limited	Formulation of benzazepine derivatives
US7955622B2 (en)	2006-10-13	2011-06-07	Actavis Group Ptc Hf	Controlled-release galantamine formulations
DE102006056697A1 (de) *	2006-11-30	2008-06-05	Ratiopharm Gmbh	Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
CA2677623C (en) *	2007-02-09	2015-04-07	Alphapharm Pty Ltd	A dosage form containing two or more active pharmaceutical ingredients in different physical forms
KR100782310B1 (ko)	2007-03-22	2007-12-06	현대약품 주식회사	갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) *	2007-08-02	2009-02-05	Drugtech Corporation	Dosage form and method of use
WO2009024858A1 (en) *	2007-08-22	2009-02-26	Aurobindo Pharma Limited	Controlled release dosage form of galantamine
EA201000585A1 (ru) *	2007-10-05	2010-10-29	КРКА, д.д., НОВО МЕСТО	Многочастичная матричная система, содержащая галантамин
EP2044933A1 (en) *	2007-10-05	2009-04-08	KRKA, D.D., Novo Mesto	Multi particulate matrix system containing galantamine
CA2615137A1 (en) *	2007-12-17	2009-06-17	Pharmascience Inc.	Single layered controlled release therapeutic system
ATE545410T1 (de)	2008-05-09	2012-03-15	Ratiopharm Gmbh	Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
US9925282B2 (en)	2009-01-29	2018-03-27	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
BR112012012766A2 (pt)	2009-11-26	2016-09-06	Usv Ltd	composicões farmacêuticas de galantamina de liberação controlada
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
GR1007767B (el)	2011-07-26	2012-11-19	Φαρματεν Αβεε,	Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
EP2911664B1 (en)	2012-10-25	2019-05-08	The General Hospital Corporation	Combination therapies for the treatment of alzheimer's disease and related disorders
US10058530B2 (en)	2012-10-25	2018-08-28	The General Hospital Corporation	Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en)	2013-05-23	2020-01-07	The General Hospital Corporation	Cromolyn compositions and methods thereof
ES2888074T3 (es)	2013-08-16	2021-12-30	Univ Maastricht	Tratamiento del deterioro cognitivo con inhibidor de PDE4
AU2014340182B2 (en)	2013-10-22	2019-05-23	The General Hospital Corporation	Cromolyn derivatives and related methods of imaging and treatment
US9849125B1 (en)	2015-11-03	2017-12-26	Banner Lifie Sciences LLC	Anti-overingestion dosage forms
GB201620095D0 (en) *	2016-11-28	2017-01-11	Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And	Novel use
CA3033079A1 (en)	2016-08-31	2018-03-08	The General Hospital Corporation	Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
EP4327871B1 (en)	2017-05-19	2025-09-24	Biscayne Neurotherapeutics, Inc.	Modified release pharmaceutical compositions of huperzine
US10335375B2 (en)	2017-05-30	2019-07-02	Patheon Softgels, Inc.	Anti-overingestion abuse deterrent compositions
KR20210070232A (ko)	2017-07-20	2021-06-14	아즈테라피즈 인코포레이티드	크로몰린 나트륨 및 이부프로펜의 분말화된 제형
US10213394B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
US10213393B1 (en)	2018-02-15	2019-02-26	Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság	Composition and method for treating neurological disease
US20190247331A1 (en)	2018-02-15	2019-08-15	Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság	Composition and method for treating neurological disease
CA3105392A1 (en)	2018-07-02	2020-01-09	The General Hospital Corporation	Powdered formulations of cromolyn sodium and .alpha.-lactose
EP3883550B1 (en)	2018-11-19	2025-03-26	Supernus Pharmaceuticals, Inc.	Use of higher doses of modified release huperzine formulations
EP3893945A4 (en)	2018-12-10	2022-11-30	The General Hospital Corporation	CROMOGLYC ESTERS AND THEIR USES
BG67408B1 (bg)	2019-04-12	2022-01-17	Софарма Ад	Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
US12458622B2 (en)	2020-04-06	2025-11-04	The General Hospital Corporation	Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE450087B (sv) *	1985-10-11	1987-06-09	Haessle Ab	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) *	1986-01-15	1987-05-05	Bonnie Davis	Method of treating Alzheimer's disease
KR100195399B1 (ko)	1987-05-04	1999-06-15	보니데이비스	알쯔하이머 병 치료용 의약
CA1326632C (en) *	1988-10-26	1994-02-01	Bonnie Davis	Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
US5085865A (en) *	1989-04-12	1992-02-04	Warner-Lambert Company	Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5519017A (en)	1990-03-29	1996-05-21	Lts Lohmann Therapie-Systeme Gmbh + Co. Kg	Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) *	1990-03-29	1991-10-02	Lohmann Therapie Syst Lts	Pharmazeutische formulierung zur behandlung des alkoholismus
AT397345B (de)	1990-04-04	1994-03-25	Chemiefaser Lenzing Ag	Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) *	1990-04-18	1996-10-09	旭化成工業株式会社	球状核、球形顆粒およびその製造方法
DE69229781T2 (de) *	1991-05-14	2000-01-05	Ernir Snorrason	Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) *	1991-05-14	1994-08-09	Ernir Snorrason	Method of treating mania in humans
US5213811A (en) *	1991-09-13	1993-05-25	Sterling Drug Inc.	Oral sustained-release drug compositions
US5229135A (en) *	1991-11-22	1993-07-20	Prographarm Laboratories	Sustained release diltiazem formulation
DE4301783C1 (de) *	1993-01-23	1994-02-03	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DE4301782C1 (de)	1993-01-23	1994-08-25	Lohmann Therapie Syst Lts	Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DK0707475T3 (da) *	1993-06-14	1997-12-29	Janssen Pharmaceutica Nv	Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
DE4319760A1 (de) *	1993-06-15	1994-12-22	Bayer Ag	Ipsapiron Arzneimittelzubereitung
CA2161538A1 (en) *	1993-07-22	1995-02-02	S. Shirley Yang	Controlled release tacrine drug delivery systems and methods for preparing same
HU218673B (hu) *	1993-10-07	2000-10-28	Euroceltique S.A.	Opioid analgetikumot tartalmazó elnyújtott hatóanyag-felszabadítású orális gyógyszerkészítmény és eljárás előállítására
US6323196B1 (en)	1993-10-15	2001-11-27	Aventis Pharmaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en)	1993-10-15	2001-11-27	Aventis Pharmaceuticals Inc.	Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) *	1993-12-10	1995-05-11	Lohmann Therapie Syst Lts	Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) *	1995-04-28	1996-09-24	Andrx Pharmaceuticals, Inc.	Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en)	1995-07-19	1995-09-20	Sod Conseils Rech Applic	Galanthamine derivatives
JP3833314B2 (ja) *	1995-09-08	2006-10-11	武田薬品工業株式会社	発泡性組成物およびその製造方法
JP3693270B2 (ja) *	1995-10-12	2005-09-07	旭化成ケミカルズ株式会社	フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) *	1995-12-19	1995-12-19	Jan Hedner	Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) *	1996-03-07	2001-02-13	武田薬品工業株式会社	放出制御組成物
TW506836B (en) *	1996-06-14	2002-10-21	Janssen Pharmaceutica Nv	Fast-dissolving galanthamine hydrobromide tablet
KR20000057154A (ko) *	1996-11-19	2000-09-15	데이비드 엠 모이어	복약 이행을 위한 포장 및 복합 약물 처방에 대한 환자의 복약 이행을 개선 또는 촉진하는 방법
JPH10231242A (ja)	1997-02-20	1998-09-02	Taiyo Yakuhin Kogyo Kk	持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
TW477702B (en) *	1997-10-23	2002-03-01	Dev Center Biotechnology	Controlled release tacrine dosage form
WO1999021561A1 (en)	1997-10-29	1999-05-06	Davis Bonnie M	Method for treatment of disorders of attention
JP5558648B2 (ja)	1998-11-23	2014-07-23	デイビス、ボニー	アセチルコリンエステラーゼ阻害剤のための投与製剤
OA11740A (en) *	1998-12-24	2005-05-13	Janssen Pharmaceutica Nv	Controlled release galantamine composition.
AUPP891299A0 (en)	1999-02-26	1999-03-25	Fujisawa Pharmaceutical Co., Ltd.	New 6-membered cyclic compounds
US6273260B1 (en) *	2000-03-08	2001-08-14	Eli Lilly And Company	Pharmaceutical packaging system

1999
- 1999-12-20 OA OA1200100170A patent/OA11740A/en unknown
- 1999-12-20 ES ES99965527T patent/ES2211215T3/es not_active Expired - Lifetime
- 1999-12-20 DE DE69912311T patent/DE69912311T2/de not_active Expired - Lifetime
- 1999-12-20 EE EEP200100319A patent/EE04996B1/xx unknown
- 1999-12-20 HU HU0104778A patent/HUP0104778A3/hu unknown
- 1999-12-20 US US09/868,991 patent/US7160559B1/en not_active Expired - Lifetime
- 1999-12-20 TR TR2001/01822T patent/TR200101822T2/xx unknown
- 1999-12-20 WO PCT/EP1999/010257 patent/WO2000038686A1/en not_active Ceased
- 1999-12-20 KR KR10-2001-7006141A patent/KR100437105B1/ko not_active Expired - Lifetime
- 1999-12-20 PL PL99349501A patent/PL349501A1/xx not_active Application Discontinuation
- 1999-12-20 AP APAP/P/2001/002219A patent/AP1414A/en active
- 1999-12-20 AT AT99965527T patent/ATE252386T1/de active
- 1999-12-20 BR BR9916835-9A patent/BR9916835A/pt not_active Application Discontinuation
- 1999-12-20 DK DK99965527T patent/DK1140105T3/da active
- 1999-12-20 EP EP99965527A patent/EP1140105B1/en not_active Expired - Lifetime
- 1999-12-20 EA EA200100713A patent/EA004936B1/ru not_active IP Right Cessation
- 1999-12-20 PT PT99965527T patent/PT1140105E/pt unknown
- 1999-12-20 AU AU21006/00A patent/AU775914B2/en not_active Expired
- 1999-12-20 ID IDW00200101372A patent/ID29021A/id unknown
- 1999-12-20 IL IL14389999A patent/IL143899A0/xx active IP Right Grant
- 1999-12-20 UA UA2001064400A patent/UA79578C2/uk unknown
- 1999-12-20 SK SK886-2001A patent/SK287676B6/sk not_active IP Right Cessation
- 1999-12-20 SI SI9930484T patent/SI1140105T1/xx unknown
- 1999-12-20 CN CNB998149888A patent/CN100370990C/zh not_active Expired - Lifetime
- 1999-12-20 NZ NZ511643A patent/NZ511643A/en not_active IP Right Cessation
- 1999-12-20 JP JP2000590639A patent/JP2002533396A/ja active Pending
- 1999-12-20 HR HR20010463A patent/HRP20010463B1/xx not_active IP Right Cessation
- 1999-12-20 CA CA002358062A patent/CA2358062C/en not_active Expired - Lifetime
- 1999-12-20 CZ CZ20012182A patent/CZ301658B6/cs not_active IP Right Cessation
- 1999-12-23 AR ARP990106725A patent/AR022008A1/es not_active Application Discontinuation
- 1999-12-23 TW TW088122698A patent/TWI262079B/zh not_active IP Right Cessation
- 1999-12-23 MY MYPI99005716A patent/MY122411A/en unknown
2001
- 2001-06-05 BG BG105564A patent/BG65306B1/bg unknown
- 2001-06-08 NO NO20012857A patent/NO327988B1/no not_active IP Right Cessation
- 2001-06-21 IL IL143899A patent/IL143899A/en not_active IP Right Cessation
- 2001-06-21 ZA ZA200105132A patent/ZA200105132B/en unknown
2005
- 2005-10-31 US US11/262,668 patent/US20060062856A1/en not_active Abandoned
- 2005-12-15 US US11/304,128 patent/US20060093671A1/en not_active Abandoned
2008
- 2008-04-25 AR ARP080101771A patent/AR066313A2/es unknown

Also Published As

Publication number	Publication date
AR066313A2 (es)	2009-08-12
HRP20010463A2 (en)	2002-08-31
HRP20010463B1 (hr)	2011-02-28
AU2100600A (en)	2000-07-31
CZ301658B6 (cs)	2010-05-19
ZA200105132B (en)	2002-06-21
SK287676B6 (sk)	2011-05-06
OA11740A (en)	2005-05-13
NZ511643A (en)	2003-07-25
EE04996B1 (et)	2008-04-15
EE200100319A (et)	2002-10-15
EA004936B1 (ru)	2004-10-28
US20060062856A1 (en)	2006-03-23
SK8862001A3 (en)	2002-02-05
BG65306B1 (bg)	2008-01-31
IL143899A0 (en)	2002-04-21
ATE252386T1 (de)	2003-11-15
EA200100713A1 (ru)	2001-12-24
SI1140105T1 (en)	2004-04-30
TWI262079B (en)	2006-09-21
CN100370990C (zh)	2008-02-27
BG105564A (en)	2002-01-31
HUP0104778A2 (hu)	2002-04-29
HK1043062A1 (zh)	2002-09-06
US20060093671A1 (en)	2006-05-04
CA2358062C (en)	2006-12-19
DK1140105T3 (da)	2004-02-23
DE69912311T2 (de)	2004-07-29
AU775914B2 (en)	2004-08-19
US7160559B1 (en)	2007-01-09
UA79578C2 (en)	2007-07-10
KR100437105B1 (ko)	2004-06-23
AR022008A1 (es)	2002-09-04
AP2001002219A0 (en)	2001-09-30
NO327988B1 (no)	2009-11-02
BR9916835A (pt)	2001-09-25
NO20012857D0 (no)	2001-06-08
KR20010075715A (ko)	2001-08-09
AP1414A (en)	2005-06-13
CZ20012182A3 (cs)	2002-01-16
ES2211215T3 (es)	2004-07-01
EP1140105B1 (en)	2003-10-22
NO20012857L (no)	2001-06-08
CN1331596A (zh)	2002-01-16
TR200101822T2 (tr)	2001-11-21
HUP0104778A3 (en)	2004-05-28
EP1140105A1 (en)	2001-10-10
JP2002533396A (ja)	2002-10-08
PL349501A1 (en)	2002-07-29
CA2358062A1 (en)	2000-07-06
PT1140105E (pt)	2004-03-31
IL143899A (en)	2006-04-10
DE69912311D1 (de)	2003-11-27
WO2000038686A1 (en)	2000-07-06
MY122411A (en)	2006-04-29

Publication	Publication Date	Title
ID29021A (id)	2001-07-26	Komposisi galantamina pelepasan terkontrol
PT945132E (pt)	2004-08-31	Composicao de ibuprofeno
ID26186A (id)	2000-12-07	Komposisi sampo
ID28694A (id)	2001-06-28	Komposisi sampo
ID26926A (id)	2001-02-22	Komposisi shampo pembentuk mode
ID27092A (id)	2001-03-01	Pembuatan ftalat anhidrida
IS2325B (is)	2007-12-15	Örgerðar samsetningar epleróns
ID29430A (id)	2001-08-30	Komposisi herbisida
PT1066027E (pt)	2003-12-31	Composicao farmaceutica de topiramato
PT1032542E (pt)	2004-11-30	Composicao de la mineral
CY2012029I2 (el)	2015-08-05	Nεα μορφη της 5-ομεπραζολης
DE69926237D1 (de)	2005-08-25	Beschichtungszusammensetzung
DE69913233T2 (de)	2004-10-21	Kosmetische Zusammensetzung
DE69931501D1 (de)	2006-06-29	Kosmetische zusammensetzung
ID25508A (id)	2000-10-05	Komposisi dematologis
DE69942892D1 (de)	2010-12-09	Gaserzeugende zusammensetzung
DE69928862D1 (de)	2006-01-19	Zusammensetzung
DE69902473D1 (de)	2002-09-12	Kosmetikzusammensetzung
DE69919480D1 (de)	2004-09-23	Beschichtungszusammensetzung
DE69930841D1 (de)	2006-05-24	Deodorantzusammensetzung
ID30226A (id)	2001-11-15	Komposisi penat rambut
ID23250A (id)	2000-03-30	Komposisi paroksetin
TR199903132A3 (tr)	2000-07-21	Metalosan bilesiklerinin aktive edici kompozisyonu.
ID21906A (id)	1999-08-12	Komposisi adesif
ID18832A (id)	1998-05-14	Komposisi insektisida